31948-87-5

Usage

Uses

Used in Organic Synthesis:
3-BROMO-5-IODOANILINE is used as a key intermediate in organic synthesis for the production of a variety of organic chemicals. Its unique structure and reactivity make it a valuable component in the creation of complex organic molecules.
Used in Pharmaceutical Research:
In the pharmaceutical industry, 3-BROMO-5-IODOANILINE is utilized as a starting material or building block in the development of new drugs. Its reactivity allows for the synthesis of diverse biologically active compounds with potential therapeutic applications.
Used in Dye Production:
3-BROMO-5-IODOANILINE is employed as a precursor in the production of dyes, particularly those requiring specific color properties. Its chemical structure contributes to the color characteristics of the resulting dyes.
Used in Agrochemical Production:
In the agrochemical industry, 3-BROMO-5-IODOANILINE is used as a component in the synthesis of various agrochemicals, such as pesticides and herbicides. Its reactivity and ability to form stable compounds make it suitable for this application.
Used in Specialty Chemicals Manufacturing:
3-BROMO-5-IODOANILINE is also used in the manufacturing of specialty chemicals, where its unique properties and reactivity are leveraged to create high-value products for specific applications.
It is crucial to handle 3-BROMO-5-IODOANILINE with care due to its hazardous nature if not properly managed.

InChI:InChI=1/C6H5BrIN/c7-4-1-5(8)3-6(9)2-4/h1-3H,9H2

Upstream product

• 875-51-4 4-Bromo-2-nitroaniline 
• 188815-32-9 3-bromo-5-iodo-benzoic acid 
• 915413-41-1 3-bromo-5-iodobenzoylazide 
• 915413-42-2 (3-bromo-5-iodophenyl)carbamic acid tert-butyl ester 
• 861601-15-2 1-bromo-3-iodo-5-nitrobenzene 

Downstream Products

• 1000289-32-6 1-benzoyl-3-(3-bromo-5-iodophenyl)thiourea 
• 915413-43-3 (3-bromo-5-iodo-phenyl)-carbamic acid methyl ester 
• 915413-54-6 N-(3-bromo-5-(6-methoxypyridin-3-yl)phenyl)acetamide 
• 1260030-06-5 N-(3-bromo-5-(pyridin-4-yl)phenyl)methanesulfonamide 
• 1260030-07-6 C₃₁H₃₉N₃O₂Si 
• 915413-46-6 N-(3-bromo-5-iodophenyl)acetamide 
• 915413-50-2 N-(3-bromo-5-iodophenyl)methanesulfonamide 
• 1000289-33-7 (3-bromo-5-iodophenyl)thiourea 
• 915413-44-4 (3-bromo-5-pyridin-3-yl-phenyl)-carbamic acid methyl ester 
• 62606-00-2 3-bromo-5-(methylsulfonyl)aniline 
• 62606-01-3 3-iodo-5-(methylsulfonyl)aniline 

Relevant academic research and scientific papers

Potent and Highly Selective Aldo-Keto Reductase 1C3 (AKR1C3) Inhibitors Act as Chemotherapeutic Potentiators in Acute Myeloid Leukemia and T-Cell Acute Lymphoblastic Leukemia

Aldo-keto reductase 1C3 (AKR1C3) catalyzes the synthesis of 9α,11β-prostaglandin (PG) F2α and PGF2α prostanoids that sustain the growth of myeloid precursors in the bone marrow. The enzyme is overexpressed in acute myeloid leukemia (

HIGHLY SELECTIVE AKR1C3 INHIBITORS AND METHODS OF USE THEREOF

The present invention includes methods and compositions that inhibit AKR1C3 enzymatic activity and consequently reduces androgen receptor (AR) transactivation, AR and prostate specific antigen (PSA) expression levels in, for example, prostate cancer, cast

Synthesis and pharmacological evaluation of N -(3-(1 H -Indol-4-yl)-5-(2- methoxyisonicotinoyl)phenyl)methanesulfonamide (LP-261), a potent antimitotic agent

The synthesis and optimization of a series of orally bioavailable 1-(1H-indol-4-yl)-3,5-disubstituted benzene analogues as antimitotic agents are described. A functionalized dibromobenzene intermediate was used as a key scaffold, which when modified by sequential Suzuki coupling and Buchwald-Hartwig amination provided a flexible entry to 1,3,5-trisubstituted phenyl compounds. A 1H-indol-4-yl moiety at the 1-position was determined to be a critical feature for optimal potency. The compounds have been shown to induce cell cycle arrest at the G2/M phase and demonstrate efficacy in both cell viability and cell proliferation assays. The primary site of action for these agents is revealed by their colchicine competitive inhibition of tubulin polymerization, and a computational model has been developed for the association of these compounds to tubulin. An optimized lead LP-261 significantly inhibits growth of a human non-small-cell lung tumor (NCI-H522) in a mouse xenograft model.

Anti-cancer agents and uses thereof

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3-R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, prostate, non-small cell lung and colon. They are additionally useful in the treatment of proliferative retinopathies such as diabetic neuropathy and macular degeneration.

ANTI-CANCER AGENTS ANS USES THEREOF

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula (I): and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3 R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6- 10 carbons in the ring portion, an optionally-substituted 6- membered heteroaryl group having 1- 3 nitrogen atoms in the ring portion, an optionally-substituted 5- membered heteroaryl group having 0- 4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6- membered ring is fused either to a 5- membered ring or to a 6- membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, prostate, non-small cell lung and colon. They are additionally useful in the treatment of proliferative retinopathies such as diabetic neuropathy and macular degeneration.

ANTIBACTERIAL COMPOSITIONS

Compounds of formula (I) have antibacterial activity: wherein: m is 0 or 1 ; Q is hydrogen or cyclopropyl; AIk is an optionally substituted, divalent C1-C6 alkylene, alkenylene or alkynylene radical which may contain an ether (-O-), thioether (-S-) or amino (-NR)- link, wherein R is hydrogen, -CN or C1-C3 alkyl; X is -C(=O)NR6-, -S(O)NR6-, -C(=O)O- or -S(=O)O- wherein R6 is hydrogen, optionally substituted C1-C6 alkyl, C2-C6 alkenyl, C2-C6 alkynyl, -Cyc, or -( C1-C3 alkyl)-Cyc wherein Cyc is optionally substituted monocyclic carbocyclic or heterocyclic having 3-7 ring atoms; Z is N or CH, or CF; R2 and R3 are as defined in the description.

Anti-cancer agents and uses thereof

The present invention is in the area of novel compounds and salts thereof, their syntheses, and their use as anti-cancer agents. The compounds include compounds of Formula I: and solvates, hydrates and pharmaceutically-acceptable salts thereof, wherein A1 is N or CR1; A3 is N or CR3; A5 is N or CR5; R1, R3—R6 and L are defined in the specification; n is 0 or 1; and X is an optionally-substituted aryl group having 6-10 carbons in the ring portion, an optionally-substituted 6-membered heteroaryl group having 1-3 nitrogen atoms in the ring portion, an optionally-substituted 5-membered heteroaryl group having 0-4 nitrogen atoms in the ring portion and optionally having 1 sulfur atom or 1 oxygen atom in the ring portion, or an optionally-substituted heteroaryl group in which a 6-membered ring is fused either to a 5-membered ring or to a 6-membered ring, wherein in each case 1, 2, 3 or 4 ring atoms are heteroatoms independently selected from nitrogen, oxygen and sulfur. They are effective against a broad range of cancers, especially leukemia, non-small cell lung and colon.